CD14 Gene (−159 C>T) Polymorphism and its Surface Expression on Monocytes in Pulmonary Tuberculosis Patients by Ali, Atia et al.
Open Access Maced J Med Sci. 2020 May 11; 8(A):203-207. 203
Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia
Open Access Macedonian Journal of Medical Sciences. 2020 May 11; 8(A):203-207.
https://doi.org/10.3889/oamjms.2020.3723
eISSN: 1857-9655
Category: A - Basic Sciences
Section:  Genetics
CD14 Gene (−159 C>T) Polymorphism and its Surface Expression 
on Monocytes in Pulmonary Tuberculosis Patients
Atia Ali, Romeeza Tahir, Faheem Shahzad, Muhammad Kashif, Shah Jahan, Nadeem Afzal*
Department of Immunology, University of Health Sciences, Lahore, Pakistan
Abstract
BACKGROUND: Tuberculosis (TB) is an infectious disease that affects millions of people around the world. The 
innate immune response against TB starts by interaction of several receptors on monocytes with mycobacterium 
tuberculosis (MTB). CD14 is one of these receptors present on the monocytes which facilitate the entry of MTB 
into the cell. Certain polymorphisms in CD14 gene, for example, CD14 (−159 C>T) in the promotor region have 
suggested susceptibility of TB. 
AIM: This study was designed to determine and compare CD14 (−159 C>T) gene polymorphism and its surface 
expression in pulmonary TB patients (before and during anti-TB treatment) and healthy controls.
MATERIALS AND METHODS: The study population comprised three groups (pulmonary TB patients before 
treatment, pulmonary TB patients during treatment, and healthy controls) whereas 53 blood samples were collected 
from each group. The percentage of monocytes and CD14 mean fluorescence intensity (MFI) was measured by 
flow cytometry whereas polymerase chain reaction-restriction fragment length polymorphism was used to determine 
gene polymorphism.
RESULTS: CD14 MFI was significantly high in healthy controls than in TB patients (432 as compared to 193 and 
365, p < 0.0001). There was no significant difference in CD14 single nucleotide polymorphism allele frequencies or 
genotypes between TB patients and healthy controls.
CONCLUSION: CD14 gene (−159 C>T) polymorphism was not associated with pulmonary TB disease in a sample 
of Pakistani population and surface expression of CD14 receptor on peripheral blood monocytes decreases with 
active TB disease and during treatment.
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Introduction
Tuberculosis (TB) is a bacterial infectious 
disease caused by an acid-fast bacillus; i.e., 
mycobacterium tuberculosis (MTB). Approximately 
one-third of the world’s population is infected with 
MTB; however, a relatively small proportion (5–10%) 
of infected individuals develops TB disease during 
their lifetime [1]. Mortality rate of TB has reached up 
to 1.5–2 million deaths per year; hence, it became 
second high mortality rate disease after HIV/AIDS [2]. 
More than half of the world’s TB cases (54%) had been 
reported in Asia. Pakistan ranks fifth among high TB 
burden countries where its mortality rate is 26 cases 
per 100,000 individuals [3].
The host defense mechanisms start with the 
recognition of MTB by phagocytic cells which bear 
germ-line encoded pattern recognition receptors (PRR) 
on their surface [4], [5]. CD14 is one of these receptors 
encoded by human CD14 gene located on chromosome 
5q31.3 [6].
CD14 is a multifunctional glycoprotein antigen 
that is mainly expressed on monocytes and serves as 
the marker of identification. It contributes to receptor 
mediated uptake of non-opsonized MTB through 
recognizing mycobacterial cell wall components, 
such as lipoarabinomannan, lipoteichoic acid, and 
lipoproteins [7]. Activated macrophages upregulate 
some of their PRRs expression, while CD14 expression 
is decreased in active TB infection [8].
The blood signatures are promising marker 
of TB which not only correlates with the magnitude 
of radiographic findings of the disease but it is also 
moderated on effective treatment [9]. Variations in 
the percentage of circulating monocytes and their 
subsets during MTB infection have already been 
documented [10], [11].
Host’s genetic factors also influence the extent 
of immune response and hence determine the fate of MTB 
infection as clinical or sub-clinical [12]. Single nucleotide 
polymorphism (SNP) of the CD14 gene (−159C>T) 
at position rs2569190 is close to the recognition 
site of Sp1 transcription factor, and mutant allele T 
genotype is associated with the increased expression 
of CD14 [13], [14]. The studies have suggested that 
CD14-159TT genotype (rs2569190) could be a risk 
factor for pulmonary TB [15], [16], [17], [18]. Therefore, 
this study was designed to determine CD14 gene (−159 
C>T) polymorphism and surface expression of CD14 
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receptor on monocytes before and during treatment of 
pulmonary TB patients in a local population.
Materials and Methods
It was a cross-sectional comparative study 
conducted during April 2017–April 2018 in the 
Department of Immunology University of Health 
Sciences (UHS) Lahore Pakistan after approval of 
Ethical Review Committee of UHS and Gulab Devi 
Hospital Lahore.
Study subjects
A total of 159 subjects were recruited from 
the Gulab Devi Chest Hospital Lahore and they were 
made into three groups of 53 individuals in each, 
i.e., pulmonary TB patients before anti-TB treatment, 
during treatment, and healthy individuals as controls. 
Pulmonary TB patients were diagnosed on the basis 
of sputum smear microscopy and chest X-ray. Age, 
gender, and ethnicity matched unrelated individuals 
having neither history nor current signs and symptoms 
of TB infection were recruited as healthy controls. After 
obtaining a written informed consent 3 ml of venous 
blood of all the subjects was drawn in EDTA tube.
Flow cytometric analysis for mCD14
The peripheral blood leukocytes were isolated 
using lyse-wash method from freshly collected EDTA 
blood. Monocytes were stained using monoclonal anti-
human CD14-FITC and CD45-PerCP antibodies for 
10 min at 4°C. The final cell suspension was prepared 
using 500 μl of ×1 sheath fluid. Processed samples 
were acquired and analyzed on FACSCalibur (BD, USA) 
using software CellQuest. At least 50,000 events were 
analyzed and percentage of CD45+CD14+ monocytes 
and CD14 mean fluorescence intensity (MFI) was 
determined.
Polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP) for 
SNP analysis of CD14 gene
Genomic DNA was extracted using phenol 
chloroform method from the whole blood [19]. 
PCR was carried out using 100 ng/uL of extracted 
DNA and specific set of primers (Forward 
5’-TAGATTCTCTGGGATATAAGG-3’ and Reverse 
5’-CTGACAGTTTATGTAATCCTG-3’). DNA was initially 
denatured at 94°C for 5 min. The cycling conditions 
were set as denaturation at 95°C for 30 s, annealing 
at 56°C for 30 s, and extension at 72°C for 45 s for 
35 cycles followed by the final extension at 72°C for 
5 min. The amplified PCR product was digested 
with restriction endonuclease, Eco47I (10 units/uL) 
followed by electrophoresis using 2% agarose gel to 
identify different genotypes. The band size of 357 bp 
indicated CC genotype, 357–217–140 bp indicated CT 
heterozygous genotype, and 217–140 bp showed TT 
genotype [20].
Statistical analysis
The data were entered and analyzed using 
SPSS 20.0. Mean ± SD was calculated for quantitative 
variables whereas frequencies were calculated for 
qualitative variables. Data were analyzed using 
Pearson’s Chi-Square test, one-way ANOVA and post 
hoc Tukey’s test. Polymorphism analysis and allele 
frequencies of CD14 (−159 C>T) were compared 
among the groups using Chi-square test. Odds ratios 
(OR) and confidence intervals (CIs) were calculated 
using logistic regression. p ≤ 0.05 was considered as 
statistically significant.
Results
Demographic data of study subjects
Demographic data of 106 pulmonary TB patients 
and 53 healthy controls are shown in Table 1. Mean 
age was compared between groups using independent 
sample t-test (mean difference = 7.1). A positive 
correlation of history of smoking and household contact 
was detected with TB (21.6% as compared to 7.4%, 
p = 0.01, OR, 95% CI = 1.3 and 21.6% as compared to 
9.4%, p = 0.02, OR, 95% CI = 1.3, respectively).
Table 1: Demographic data of the study subjects
Variables Pulmonary TB 
cases (n=106)
Healthy 
controls (n=53)
p-value Odds ratio 
(95% CI)
Age (years)
Mean±SD 39.14±16.2 32.06±11.5
Gender
Male n (%) 44 (41.5) 30 (56.6)
Female n (%) 62 (58.4) 23 (43.3)
Smoking history n (%) 23 (21.6) 4 (7.4) 0.01* 1.3, 1.1~1.6
Contact history n (%) 23 (21.6) 5 (9.4) 0.02* 1.3, 1.0~1.6
MDR n (%) 6 (5.6) ----
n=Number, %=Percentage, *p<0.05=Statistically significant. MDR: Multidrug-resistant, CI: Confidence 
intervals, TB: Tuberculosis.
Identification and comparison of 
CD45+CD14+ monocytes by flow cytometry
Monocytes were gated first at forward and side 
scatter plots followed by intersecting two antibodies 
gates. CD45/CD14 double positive population was 
gated (Figure 1).
The percentage of CD45+ CD14+ monocytes 
and CD14 MFI was compared among TB patients 
before and after anti-TB treatment and healthy controls 
 Ali et al. CD14 in Pulmonary Tuberculosis Patients
Open Access Maced J Med Sci. 2020 May 11; 8(A):203-207. 205
(Table 2). The percentage of CD45+CD14+ monocytes 
was compared using one-way ANOVA where its mean 
between groups, homozygous TT was slightly higher in 
pulmonary TB patients as compared to healthy controls 
(26.4% as compared to 22.6%), but the difference was 
not statistically significant. The association of exposure 
to T allele and pulmonary TB disease was determined 
using Pearson’s Chi-square test. The comparison 
showed no statistically significant difference.
The CD14 MFI was compared with CD14 (−159 
C>T) genotypes and alleles using one-way ANOVA and 
independent sample t-test, respectively (Table 4). There 
was no statistically significant difference for median CD14 
MFI among CC, CT, and TT genotypes. Mean CD14 
MFI was slightly higher for C allele than T allele (398 as 
compared to 351), but it was not statistically significant.
Table 4: Comparison of CD14 mean fluorescence intensity with 
CD14 (−159 C>T) genotypes and alleles
Variables CD14 mean fluorescence  
intensity (Mean±SD)
p-value
Genotypes 
CC 398±201.5 0.2
CT 329±165.7
TT 378±174.8
Alleles
C 398±201 0.1
T 351±170
p≤0.05=statistically significant.
Discussion
In the current study, 53 individuals in each 
group, i.e., TB patients before the treatment, after 
anti-TB therapy and healthy controls were included 
and compared for CD14 gene polymorphism and 
surface expression on monocytes. Since monocytes/
macrophages have been documented as chief effector 
cells in defending the host against MTB infection [11], 
therefore, current study determined percentage of 
peripheral blood CD45+CD14+ monocytes in TB patients 
before and during treatment and in healthy controls. 
There was no significant difference among the groups. 
This finding is in contrast with the previous study which 
documented an increase in monocyte compartment 
of peripheral blood in active TB disease [21]. 
Rakotosamimanana et al. observed reduced fraction of 
white blood cell count and in particular, monocyte on 
completion of TB treatment [22].
CD14 MFI in CD45+CD14+ monocytes was 
compared among study groups to determine the effect 
of treatment on mCD14. There was highly significant 
difference in CD14 MFI among the three groups 
Figure 1: Representative flow cytometric analysis of peripheral blood 
monocytes in the study cohort. (a) Leukocytes on forward and side 
scatter with monocytes in encircled area. (b) Isotype control run on 
CD45-PerCP and CD14-FITC plot. (c) FACS plot for CD45-PerCP 
and CD14-FITC of representative sample showing gated double 
positive population in R2 and expressed in percentage of cells. 
(d) Histogram of CD14-FITC expression on CD45+CD14+ monocytes 
presented as mean fluorescence intensity
was high in TB patients on treatment than TB patients 
before treatment and healthy controls (6.1% as 
compared to 5.6% and 5.7%) and the difference among 
these groups was not statistically significant. The median 
of CD14 MFI was compared using Kruskal–Wallis test 
which was high in healthy controls as compared to TB 
patients before and after treatment and the difference 
was statistically significant (432 as compared to 
365 and 193, p < 0.0001) whereas treatment naïve 
TB patients had high CD14 MFI than TB patients on 
treatment and its difference was statistically significant 
(365 as compared to 193, p < 0.0001).
Table 2: Comparison of percentage of CD45+CD14+monocytes 
and CD14 mean fluorescence intensity among the studied 
groups
Variables Pulmonary TB 
patients before 
treatment
Pulmonary 
TB patients 
on treatment
Healthy 
controls
p-value
CD45+CD14+ (%)
Mean±SD 5.6±2.2 6.1±2 5.7±1.8 0.2
CD14 mean 
fluorescence intensity
Median 365 193 432 <0.0001*
Range 105–935 66–693 166–964
*p<0.05=Statistically significant. TB: Tuberculosis.
CD14 (−159 C>T) SNP genotype and allele 
frequencies in pulmonary TB patients and healthy 
controls are shown in Table 3. Homozygous CC 
genotype was more frequent in overall study population 
as compared to TT genotype. While comparing 
Table 3: Comparison of CD14 (−159 C>T) genotype frequencies 
between study groups
Variables TB patients Healthy controls p-value
Genotypes
CC n (%) 49 (46.2) 26 (49.0) 0.082
CT n (%) 29 (27.3) 15 (28.3)
TT n (%) 28 (26.4) 12 (22.6)
Alleles
C n (%) 127 (59.9) 67 (63.2) 0.8
C+T n (%) 85 (40.1) 39 (36.7)
n=Number, %=Percentage, p≤0.05=Statistically significant. TB: Tuberculosis.
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(p < 0.0001). It was noted that healthy subjects had 
the highest CD14 MFI followed by TB patients before 
the therapy whereas patients on anti-TB treatment had 
the lowest CD14 MFI. These findings are consistent 
with Guirado et al. who suggested that activated 
mononuclear phagocytes have increased PRR 
expression, particularly of mannose receptor, while 
CD14 expression was decreased during active TB 
infection [8].
The innate immune response is also regulated 
by CD14 gene polymorphism [23]. The current study 
determined the prevalence of CD14 (−159 C>T) 
gene polymorphism by PCR-RFLP technique and 
investigated its correlation with the status of TB disease. 
It was detected that CC genotype was more prevalent 
in the overall study cohort while TT genotype was more 
common in TB patients than in healthy controls (26% as 
compared to 22%). Similarly, while comparing alleles 
between the study groups, mutant T allele was more 
common in TB patients than in healthy controls, but the 
difference was not statistically significant. For CD14 
(−159 C>T) SNP, C allele is a reference allele in the 
Asian population [24]. The results of the current study 
are in agreement with Ayaslioglu et al. (2013) who also 
performed SNP genotyping through PCR-RFLP and 
could not detect significant difference in allelic as well 
as in genotype distribution between TB patients [19].
A study performed in Chinese population 
documented high frequency of T allele in C (−159) T 
polymorphism (OR 1.4, CI 95%) in TB patients than 
in controls [17]. Alavi-Naini et al. reported 2.3-fold 
increased risk of TB disease in individuals with T allele 
as compared to those without it [25]. In the present 
study, there was no significant association of T allele 
with TB disease susceptibility. The reason may be 
because the current study included genetically different 
population and smaller cohort.
To investigate whether CD14 (−159 C>T) 
SNP genotypes have impact on expression of mCD14 
on monocyte surface, the current study compared 
genotypes and alleles with CD14 MFI on CD45+CD14+ 
monocytes and no statistically significant effect of CD14 
MFI with different CD14 SNP genotypes as well as C or 
T alleles was detected. However, T allele had slightly 
decreased CD14 MFI as compared to C allele. On the 
contrary to this, it was reported that mutant allele T 
genotype is associated with the increased expression 
of CD14 [13].
Conclusion
CD14 gene (−159 C>T) polymorphism was 
not associated with pulmonary TB disease in a sample 
of Pakistani population and therefore does not support 
this SNP for TB susceptibility. The surface expression 
of CD14 receptor on peripheral blood monocytes was 
decreased in active TB infection which further decreased 
during anti-TB treatment. It suggests the potential role of 
CD14 surface expression in monitoring anti-TB treatment.
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